Loading...
•
Jun 30, 2022
Castle Biosciences Q2 2022 Earnings Report
Reported strong financial and operational performance, driven by growth in test report volume and revenue, and raised 2022 revenue guidance.
Key Takeaways
Castle Biosciences reported a 53% increase in revenue compared to Q2 2021, reaching $34.8 million. The company delivered 11,034 total test reports, a 57% increase over the same period last year. They are raising 2022 revenue guidance to $130-135 million.
Revenue increased 53% over Q2 2021 to $34.8 million.
Total test reports delivered increased 57% compared to Q2 2021, reaching 11,034.
Skin cancer gene expression profile test report volume increased 44% compared to Q2 2021.
2022 Revenue Guidance raised to $130–135 million from $118–123 million.
Forward Guidance
Castle Biosciences is increasing its previously issued guidance for anticipated total revenue in 2022. The Company now anticipates generating $130–135 million in total revenue in 2022, compared to the previously provided guidance of $118–123 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...